Back to Markets
MGMacroGenics Inc

MacroGenics Inc

MGNXNASDAQ NMS - GLOBAL MARKET
Health CareBiotechnology

$4.16

-0.050000 (-1.19%)

As of 05/29/26 EDT · USD

Compare
Low: $1.19Current: $4.16High: $4.64

Key Statistics

Open

$4.14

Day High

$4.28

Day Low

$4.13

Prev. Close

$4.21

VolumeShares traded today.

586.93K

Avg. VolumeAverage daily volume.

Market CapTotal value of all shares = price × shares outstanding.

$264.42M

P/E (TTM)Price-to-Earnings: share price ÷ earnings per share over the last 12 months. Lower can mean cheaper; very high can mean growth expectations.

-3.74

Forward P/EP/E based on forecast next-year earnings.

P/B RatioPrice-to-Book: share price ÷ book value per share.

52W HighHighest price over the past 52 weeks.

$4.64

52W LowLowest price over the past 52 weeks.

$1.19

50D MAAverage closing price over the last 50 trading days.

$3.43

200D MAAverage closing price over the last 200 trading days.

$2.16

Dividend YieldAnnual dividend ÷ share price, as a %.

BetaVolatility vs the market. >1 = more volatile than the S&P 500.

Performance

1W

-1.9%

1M

+41.5%

6M

+186.9%

YTD

+158.4%

1Y

+199.3%

About

Teplizumab, sold under the brand name Tzield among others, is an anti-CD3 humanized monoclonal antibody that is the first approved treatment indicated to delay the onset of stage 3 type 1 diabetes in people with stage 2 type 1 diabetes.

www.macrogenics.com/

Company Facts

SectorHealth Care
IndustryBiotechnology
ExchangeNASDAQ NMS - GLOBAL MARKET
CurrencyUSD

Sentiment

Latest News

Social Noise

Price Alerts

Loading…

Trade MGNX

Brokers available in your region (US)

Affiliate links — we may earn a commission. CFDs are risky.